P. Gillman

British Journal of Pharmacology · 2007

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom P. Gillman trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Magnus Ingelman-Sundberg
  2. S. Sim

Who trusts P. Gillman overall

  1. Koustuv Saha

Papers from P. Gillman's perspective

Ordered by how strongly the researchers P. Gillman trusts endorse each paper. Same corpus, a different order for every researcher.

  1. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (Clinical pharmacology and therapy)
  2. H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs (Neuropsychopharmacology)
  3. Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications (British medical journal)
  4. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. (Journal of the American Medical Association (JAMA))
  5. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response (Molecular Psychiatry)
  6. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism (Clinical Pharmacokinetics)
  7. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity (The Pharmacogenomics Journal)
  8. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. (Journal of Clinical Oncology)
  9. Pharmacogenomics and individualized drug therapy. (Annual Review of Medicine)
  10. Drug metabolism and variability among patients in drug response. (New England Journal of Medicine)

Their papers